NEC Bio Therapeutics, a company focuses on the clinical strategy and development, as well as planning and execution of clinical trials in the oncology area, presents 24-week promising interim results ...
(MENAFN- JCN NewsWire) NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025 Phase I NECVAX-NEO1 basket trial data confirm its ...
Interim results from an ongoing clinical trial of NECVAX-NEO1 highlight its safety and immunogenicity. These results are NEC's first proof-of-concept for an investigational oral DNA vaccine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results